Melanoma Molecular Maps Projects

Padova

Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;


  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);


  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.


Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.



LATEST NEWS
The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.




REFERENCE(S):

"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site


Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |


Melanoma News

PAR-1 AND MASPIN
Protease activated receptor-1 (PAR-1) inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.
Source: Villares GJ, Proc Natl Acad Sci USA 2011, 108:626-31.

MACRO-H2A
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8.
Source: Kapoor A, Nature 2010, 468:1105-9.

CXCL9
CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells.
Source: Amatschek S, Br J Cancer 2011, 104:469-79.

News Archive